tosiben: may be useful in treating acute lung injury [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 68093 |
| CHEMBL ID | 1451173 |
| CHEBI ID | 107635 |
| SCHEMBL ID | 26164 |
| MeSH ID | M0058278 |
| Synonym |
|---|
| BRD-K47608922-001-02-1 |
| DIVK1C_006933 |
| 2,3-bis(acetyloxy)benzoic acid |
| dipyrocetyl [inn:dcf] |
| 2,3-diacetoxybenzoic acid |
| u.c.b. 5080 |
| dipirocetilo [inn-spanish] |
| pyrocat |
| 2,3-dihydroxybenzoic acid diacetate |
| movirene |
| tosiben |
| dipyrocetylum [inn-latin] |
| benzoic acid, 2,3-bis(acetyloxy)- |
| dipyrocetyl |
| einecs 207-641-7 |
| SPECTRUM_001753 |
| 486-79-3 |
| D07290 |
| dipyrocetyl (inn) |
| BSPBIO_003488 |
| SPECTRUM5_001049 |
| NCGC00095316-01 |
| KBIO2_007369 |
| KBIO1_001877 |
| KBIOGR_000855 |
| KBIO3_002708 |
| KBIO2_002233 |
| KBIOSS_002233 |
| KBIO2_004801 |
| SPECTRUM3_001754 |
| SPECPLUS_000837 |
| SPECTRUM2_000417 |
| SPECTRUM4_000218 |
| SPBIO_000374 |
| NCGC00095316-02 |
| 2,3-diacetyloxybenzoic acid |
| CHEBI:107635 |
| dipirocetilo |
| ucb 5080 |
| unii-ef5uve254c |
| dipyrocetylum |
| o-pyrocatechuic acid, diacetate |
| nsc 758212 |
| ef5uve254c , |
| tox21_111504 |
| dtxsid9045976 , |
| dtxcid7025976 |
| cas-486-79-3 |
| pharmakon1600-01503032 |
| nsc758212 |
| nsc-758212 |
| CCG-39955 |
| diacetylsalicylic acid |
| CHEMBL1451173 |
| dipyrocetyl [inn] |
| dipyrocetyl [who-dd] |
| dipyrocetyl [mi] |
| AKOS022660241 |
| SCHEMBL26164 |
| CS-4788 |
| NYIZXMGNIUSNKL-UHFFFAOYSA-N |
| HY-B1179 |
| AB00052432_02 |
| SR-01000872730-1 |
| sr-01000872730 |
| Q5280140 |
| DB13839 |
| mfcd00867838 |
| D81884 |
| BS-48970 |
| 2,3-diacetoxybenzoicacid |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Class | Description |
|---|---|
| carboxylic ester | An ester of a carboxylic acid, R(1)C(=O)OR(2), where R(1) = H or organyl and R(2) = organyl. |
| salicylates | Any salt or ester arising from reaction of the carboxy group of salicylic acid, or any ester resulting from the condensation of the phenolic hydroxy group of salicylic acid with an organic acid. |
| benzoic acids | Any aromatic carboxylic acid that consists of benzene in which at least a single hydrogen has been substituted by a carboxy group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 0.0398 | 0.0398 | 16.7842 | 39.8107 | AID995 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 40.5334 | 0.0056 | 12.3677 | 36.1254 | AID624032 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||